Literature DB >> 3167523

Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus.

C S Robertson1, J F Mayberry, D A Nicholson, P D James, M Atkinson.   

Abstract

Fifty-six patients with Barrett's oesophagus diagnosed between 1977 and 1986 were prospectively studied by 6-monthly endoscopic surveillance and biopsy. During follow-up to-date, four patients have developed high-grade dysplasia and three have adenocarcinoma of the oesophagus. Two of the adenocarcinomas were preceded by progressively severe dysplastic changes but in the third no dysplasia had been previously detected. The incidence of adenocarcinoma was 1 per 56 patient-years of follow-up. Changes in symptomatology or gross endoscopic appearances were usually absent, even after adenocarcinoma had developed, indicating that biopsy is essential for early diagnosis. The high risk of malignant change makes endoscopic surveillance advisable in all patients with Barrett's oesophagus.

Entities:  

Mesh:

Year:  1988        PMID: 3167523     DOI: 10.1002/bjs.1800750813

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  50 in total

1.  What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis.

Authors:  N J Shaheen; J M Inadomi; B F Overholt; P Sharma
Journal:  Gut       Date:  2004-12       Impact factor: 23.059

Review 2.  Gastroenterology.

Authors:  L J O'Donnell; E M Alstead; M J Farthing
Journal:  Postgrad Med J       Date:  1990-06       Impact factor: 2.401

Review 3.  Barrett's oesophagus--to screen or not to screen?

Authors:  M Atkinson
Journal:  Gut       Date:  1989-01       Impact factor: 23.059

4.  Gastroesophageal reflux disease: relationship between clinical and histological features. GOSPE. Gruppo Operativo per lo Studio delle Precancerosi dell'Esofago.

Authors:  H Aste; L Bonelli; R Ferraris; M Conio; G Lapertosa
Journal:  Dig Dis Sci       Date:  1999-12       Impact factor: 3.199

Review 5.  Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk?

Authors:  J Lagergren
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

6.  Barrett's esophagus: prevalence and risk factors in patients with chronic GERD in Upper Egypt.

Authors:  Yasser M Fouad; Madiha M Makhlouf; Heba M Tawfik; Hussein el-Amin; Wael Abdel Ghany; Hisham R el-Khayat
Journal:  World J Gastroenterol       Date:  2009-07-28       Impact factor: 5.742

7.  Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus.

Authors:  M Miros; P Kerlin; N Walker
Journal:  Gut       Date:  1991-12       Impact factor: 23.059

Review 8.  American Gastroenterological Association technical review on the management of Barrett's esophagus.

Authors:  Stuart J Spechler; Prateek Sharma; Rhonda F Souza; John M Inadomi; Nicholas J Shaheen
Journal:  Gastroenterology       Date:  2011-03       Impact factor: 22.682

Review 9.  Multimodality treatment of cancer arising from Barrett's epithelium.

Authors:  J A Roth
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

10.  Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux.

Authors:  M Solaymani-Dodaran; R F A Logan; J West; T Card; C Coupland
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.